Profound Medical Corp.

Equities

PRN

CA74319B5027

Advanced Medical Equipment & Technology

Market Closed - Toronto S.E. Other stock markets 15:16:33 2024-07-15 EDT			5-day change	1st Jan Change
12.48 ^CAD	-0.24%		+2.63%	+12.43%

07-11	Profound Medical Says U.S. Medicare Rules Proposed for TULSA Procedure	MT
07-11	Profound Medical Brief: Announcing Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases	MT

Profound Medical Corp. announced that it has received $2.937503 million in funding

January 17, 2024

On January 18, 2024, Profound Medical Corp., closed the transaction and final tranche. The company issued a total of 391,667 common shares in the capital of the Company at a price of $7.50 per Common Share for the gross proceeds of $2,937,503.

Latest news about Profound Medical Corp.

Profound Medical Says U.S. Medicare Rules Proposed for TULSA Procedure	07-11	MT
Profound Medical Brief: Announcing Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases	07-11	MT
Profound Medical Corp. Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases	07-11	CI
Transcript : Profound Medical Corp. - Shareholder/Analyst Call	05-15
Sector Update: Health Care Stocks Steady Premarket Tuesday	05-14	MT
Profound Medical Receives FDA Approval for AI-Powered Prostate Disease Device --Shares Advance Pre-Bell	05-14	MT
Profound Medical Receives U.S. FDA Clearance for "Contouring Assistant" AI Module	05-14	MT
Profound Medical Brief: Says Received U.S. FDA 510(k) Clearance for 'Contouring Assistant' AI Module that Enables Creation of an Automated TULSA Treatment Plan	05-14	MT
Profound Medical Receives U.S. FDA 510(K) Clearance for Contour Assistant AI Module That Enables Creation of an Automated Tulsa Treatment Plan	05-14	CI
Profound Reports a Narrower First-Quarter Loss; Provides 2024 Revenue Guidance	05-09	MT
Transcript : Profound Medical Corp., Q1 2024 Earnings Call, May 09, 2024	05-09
Profound Medical Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Profound Medical Brief: Expects total revenue for FY24 to be in the range of US$11.0-$12.0 million, which represents 53% to 67% growth compared to its prior year revenue	05-09	MT
Profound Medical Brief: Recorded Q1 revenue of approximately $1.91 million, with $1.48 million from recurring revenue; Issues Full-Year 2024 Revenue Guidance	05-09	MT
Profound Medical Corp. Provides Earnings Guidance for Full-Year 2024	05-09	CI
Profound Medical Says Clinical Evidence Points to Potential of Its TULSA Procedure as a Treatment for Prostate Cancer	05-06	MT
Profound Medical Brief: Adds Clinical evidence Continues to highlight TULSA's "Ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH"	05-06	MT
Profound Medical Brief: Says "Growing Body of Clinical Evidence" Points to Potential of Its TULSA Procedure "Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum"	05-06	MT
Transcript : Profound Medical Corp. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 11:15 AM	03-13
Alliance Global Partners Trims Price Target on Profound Medical to $10.80 From $12.75, Maintains Buy Rating	03-11	MT
Stifel Adjusts Price Target on Profound Medical to $9 From $11, Keeps Hold Rating	03-08	MT
Profound Medical Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
Transcript : Profound Medical Corp., Q4 2023 Earnings Call, Mar 07, 2024	03-07
Profound Medical Reports Q4 Net Loss of US$0.42 Per Share, Announces COO Appointment	03-07	MT
Profound Medical Brief: Announcing promotion of Mathieu Burtnyk, from SVP Product Leader to Chief Operating Officer	03-07	MT

Chart Profound Medical Corp.

Duration

Period

More charts

Company Profile

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum. TULSA-PRO has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer and the transition zone in large volume benign prostatic hyperplasia. It is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Profound Medical Corp.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.48

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
PROFOUND MEDICAL CORP.	+12.43%	224M
THERMO FISHER SCIENTIFIC	+2.62%	208B
DANAHER CORPORATION	+6.44%	182B
INTUITIVE SURGICAL, INC.	+29.61%	155B
BOSTON SCIENTIFIC CORPORATION	+34.96%	115B
SIEMENS HEALTHINEERS AG	+3.84%	66.52B
EDWARDS LIFESCIENCES CORPORATION	+17.38%	53.93B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-4.51%	46.26B
AGILENT TECHNOLOGIES, INC.	-5.77%	38.22B
GE HEALTHCARE TECHNOLOGIES INC.	+3.71%	36.6B

Other Advanced Medical Equipment & Technology